



66/47/60

A

PTO/SB/05 (4/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

Attorney Docket No. I/95150 US/D1

First Inventor or Application Identifier KOK

Title COCCIDIOSIS POULTRY VACCINE

Express Mail Label No. EL358032393US

**APPLICATION ELEMENTS**

See MPEP chapter 600 concerning utility patent application contents.

1.  \* Fee Transmittal Form (e.g., PTO/SB/17)  
(Submit an original and a duplicate for fee processing)

2.  Specification [Total Pages 48]  
(preferred arrangement set forth below)

- Descriptive title of the Invention
- Cross References to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to Microfiche Appendix
- Background of the Invention
- Brief Summary of the Invention
- Brief Description of the Drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the Disclosure

3.  Drawing(s) (35 U.S.C. 113) [Total Sheets 2]

4. Oath or Declaration [Total Pages 2]

- a.  Newly executed (original or copy)
- b.  Copy from a prior application (37 C.F.R. § 1.63(d))  
(for continuation/divisional with Box 16 completed)
  - i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting inventor(s) named in the prior application, see 37 C.F.R. §§ 1.63(d)(2) and 1.33(b).

\* NOTE FOR ITEMS 1 & 13: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28).

Assistant Commissioner for Patents  
ADDRESS TO: Box Patent Application  
Washington, DC 20231

5.  Microfiche Computer Program (Appendix)

6. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)

- a.  Computer Readable Copy
- b.  Paper Copy (identical to computer copy)
- c.  Statement verifying identity of above copies

**ACCOMPANYING APPLICATION PARTS**

7.  Assignment Papers (cover sheet & document(s))  
37 C.F.R. § 3.73(b) Statement  Power of  
(when there is an assignee)  Attorney

8.  English Translation Document (if applicable)

9.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS  
Statement (IDS)/PTO-1449  Citations

10.  Preliminary Amendment

11.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)

12.  \* Small Entity Statement(s)  Statement filed in prior application,  
(PTO/SB/09-12)  Status still proper and desired

13.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)

14.  Other: .....

15.  .....

16. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No: 08 / 676,882

Prior application information: Examiner J. Martin Group / Art Unit: 1632

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 4b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

**17. CORRESPONDENCE ADDRESS**

Customer Number or Bar Code Label  (Insert Customer No. or Attach bar code label here) or  Correspondence address below

Name	Mary E. Gormley			
	AKzo Nobel, N.V.			
Address	1300 Piccard Drive			
	Suite 206			
City	Rockville	State	Maryland	Zip Code
Country		Telephone	301-948-7400	Fax
				20850
				301-948-9751

Name (Print/Type)	Mary E. Gormley	Registration No. (Attorney/Agent)	34,409
Signature		Date	9/14/99

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

09/14/99

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:

Jacobus Johannes KOK, Paul van den BOOGAART and  
Arnoldus Nicholas VERMEULEN

Serial Number: To be assigned Group Art Unit: To be assigned

Filed: Concurrently herewith Examiner: To be assigned

For: COCCIDIOSIS POULTRY VACCINE

Corresponding to: Division of US Serial No. 08/676,882, filed  
July 3, 1996.

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents  
Washington, D.C. 20231

September 14, 1999

Sir:

Prior to the calculation of the fee in the above-identified application, please make the following amendments:

IN THE SPECIFICATION:

Page 1, line 2, insert -- Field of the Invention --; and  
line 12, insert -- Background of the Invention --.  
Page 6, line 6, insert -- Summary of the Invention --.  
Page 7, line 4, insert Detailed Description of the  
Invention --; and  
line 20, delete "abovenoted" and replace with  
-- above-noted --.  
Page 9, line 9, delete "so-called pepscan" and replace with  
-- Pepscan --.  
Page 10, line 15, delete "so-called".  
Page 14, line 21, delete "so-called".  
Page 17, line 2, delete "insertion-region" and replace with  
-- insertion region --;

line 21, delete "microorganisms" and replace with  
-- microorganism --; and

line 34, delete "adeno virus" and replace with  
-- adenovirus --.

Page 19, line 6, delete "immuno affinity" and replace with  
-- immunoaffinity --; and

line 7, delete "intra cellular" and replace with  
-- intracellular --.

Page 22, line 22, delete "Reo virus" and replace with  
-- Reovirus -- and delete "Retro virus" and replace with  
-- Retrovirus--; and

line 23, delete "Adeno virus" and replace with  
-- Adenovirus --.

Page 23, line 16, delete "intra-cellular" and replace with  
-- intracellular --.

Page 24, line 19, delete "TritonX114" and replace with  
-- Triton X114 --; and

line 26, delete "roomtemperature" and replace with  
-- room temperature --.

Page 25, line 8, in both instances, delete "Prep cell" and  
replace with -- Prepcell --;

line 10, delete "Dialyse" and replace with  
-- Dialysis --;

line 11, delete "Powersupply" and replace with  
-- Power supply --;

line 13, delete "bromo phenol" and replace with  
-- bromophenol --; and

line 30, delete "powersupply" and replace with  
-- power supply --.

Page 26, line 7, delete "Blotting" and replace with  
-- blotting --;

line 13, delete "Prepcellrun" and replace with  
-- Prepcell run --;

line 16, delete "acetoneprecipitation" and replace  
with -- acetone precipitation --; and

line 26, delete "amino-acid" and replace with  
-- amino acid --.

Page 27, line 4, delete "western" and replace with  
-- Western --;

line 8, delete "Prepcellruns" and replace with  
-- Prepcell runs --; and

line 15, delete "western" and replace with  
-- Western --.

Page 28, line 32, delete "booster-vaccine" and replace with  
-- booster vaccine --.

Page 29, line 23, delete "Prep cell" and replace with  
-- Prepcell".

Page 30, line 4, delete "prepcell" and replace with  
-- Prepcell --.

Page 31, line 17, delete "bloodcells" and replace with  
-- blood cells --.

Page 32, line 10, delete "store" and replace with  
-- stored --; and

line 31, delete "prepcell" and replace with  
-- Prepcell --; and

Page 33, line directly below Table 4, delete "controle" and  
replace with -- control --.

IN THE CLAIMS:

Please amend the claims as follows:

1. (amended) A protein having one or more immunoreactive and/or antigenic determinants of *Eimeria* lactate dehydrogenase (LDH) [, said LDH having a relativvve monomeric molecular mass of about 37,000].
2. (amended) [A] The protein according to claim 1, wherein the *Eimeria* species is *Eimeria acervulina*.
3. (amended) [A] The protein according to claim 1, which [characterized in that it] comprises at least part of the amino

acid sequence shown in SEQ ID NO:2 or a biologically functional equivalent thereof.

Please cancel claims 4 - 10 and 12, without prejudice or disclaimer of the subject matter thereof.

11. (amended) A vaccine for the protection of poultry against coccidiosis, which [characterized in that it] comprises a protein according to [any one of claims] claim 1 [to 3, a recombinant nucleic acid molecule according to claim 6, a recombinant vector according to claim 7 or claim 8, or a host cell or organism according to claim 9] together with a pharmaceutically acceptable carrier.

13. (amended) A process for the preparation of a coccidiosis vaccine comprising formulating a protein according to [any one of claims] claim 1 [to 3 or a protein prepared according to the process of claim 10] into a pharmaceutical preparation with immunizing activity.

14. (amended) An antibody or antiserum [immuno-reactive] immunoreactive with a protein according to [any one of claims] claim 1 [to 3].

15. (amended) A method for the protection of poultry against coccidiosis comprising administering to the poultry a vaccine according to claim 11 [to the birds].


REMARKS

Claims 1 - 3, 11 and 13 - 15 are amended and claims 4 - 10 and 12 are cancelled hereby. Claims 1 - 3, 11 and 13 - 15 are now pending.

It is believed that claims 1 - 3, 11 and 13 - 15 recite a patentable invention. Favorable action is solicited. In the

event any fees are required with this paper, please charge our  
Deposit Account No. 02-2334.

Respectfully submitted,

  
Mary E. Gormley  
Attorney for Applicants  
Registration No. 34,409

Docket No. I/95150 US/D1  
AKZO NOBEL N.V.  
1300 Piccard Drive, Suite 206  
Rockville, Maryland 20850-4373  
Tel: (301) 948-7400  
Fax: (301) 948-9751

MEG:mg

99kok.pre

## Coccidiosis poultry vaccine

The present invention relates to a protein derived from *Eimeria acervulina*, which is capable of stimulating immune lymphocytes. It also relates to a nucleic acid sequence encoding all or an antigenically significant part of this protein, a recombinant vector comprising such a nucleic acid sequence, a host cell or organism transformed with such a recombinant vector and a vaccine for the protection of poultry against coccidiosis.

Coccidiosis is a disease caused by infection with one or more of the many species of coccidia, intracellular protozoal parasites of the subphylum Apicomplexa and the genus *Eimeria*. Poultry is defined herein as domesticated birds that serve as a source of eggs or meat and that include such commercially important kinds as chickens, turkeys, ducks, geese, guinea fowl, pheasants, pigeons and peafowl.

Coccidiosis in chickens is known to be caused by several different species of *Eimeria*, namely *Eimeria acervulina*, *E. maxima*, *E. tenella*, *E. necatrix*, *E. brunetti*, *E. mitis*, *E. praecox*, *E. mivati* and *E. hagani*. Some people, however, doubt the true existence of the last two species. Low level infection with any of these *Eimeria* species results in a protective immunity to reinfection.

The species do differ in their pathogenic effect on chickens, the type of chicken also playing a role; thus, a broiler chicken will be subjected to a great deal of damage by a parasite such as *E. acervulina* or *E. maxima* because these parasitise large portions of

the small intestine, where food digestion plays a major role.

*E. acervulina* is one of the most common species found in the litter of broiler houses in both Europe and the USA. It has a great reproductive potential and is regarded as pathogenic because it produces a marked depression in gain of body weight, higher feed conversion and it produces gross lesions in the upper small intestine.

During the life cycle (see also Table 1), the *Eimeria* parasite passes through a number of stages. The life cycle begins when the chicken ingests the infectious stage, known as the sporulated oocyst, during ground feeding or by inhalation of dust. The wall of the sporulated oocyst is ruptured by a combination of mechanical grinding action and chemical action in the gizzard and intestinal tract, resulting in the release of four sporocysts. The sporocysts pass into the duodenum where they are exposed to bile and digestive enzymes resulting in the release of two sporozoites per sporocyst.

Table 1. Endogenous stages of *Eimeria acervulina* in stained sections of infected duodenum (after McDonald V. et al., *Parasitol.* 8, 21-30, 1982).

Time of infection	Histological observations
24 h	Immature 1 <sup>st</sup> generation asexual stages
36 h	Semi-mature 1 <sup>st</sup> generation schizonts
42 h	Mature 1 <sup>st</sup> gen. schizonts. Immature 2 <sup>nd</sup> gen. parasites
48 h	Mature 2 <sup>nd</sup> gen. schizonts. A few 3 <sup>rd</sup> gen. schizonts with 8-16 merozoites
60 h	Mature 3 <sup>rd</sup> gen. schizonts, immature 4 <sup>th</sup> gen. parasites

The sporozoites are mobile and search for suitable host epithelium cells in order to penetrate and reproduce in them. Following infection of an

epithelium cell, the parasite enters the schizont phase of its life cycle, producing from 8 to 16 to >200 merozoites per schizont. Once released from the schizont, the merozoites are free to infect further epithelium cells. After from two to five of these asexual reproduction cycles, the intracellular merozoites grow into sexual forms known as the female or macrogametocyte and the male or microgametocyte. Following fertilization of the macrogametocyte by the microgametes released from the microgametocyte, a zygote is formed which creates a cyst wall about itself. The newly formed oocyst is passed out of the infected chicken with the droppings.

With the correct environmental conditions of temperature and humidity and sufficient oxygen in the air, the oocyst will sporulate into the infectious stage, ready to infect a new host and thereby spreading the disease. Thus no intermediate host is required for transfer of the parasite from bird to bird.

The result of the *Eimeria* parasite infecting the digestive tract of a chicken may be a reduction in weight gain, increased feed conversion, cessation of egg production and, in some cases, death. The increase in intensive production of poultry has been accompanied by severe losses due to this parasite; indeed, coccidiosis has become the most economically important parasitic disease. In the Netherlands, the losses that poultry farmers suffer every year run into millions of guilders; in 1986 the loss was about 13 million guilders. In the same year, a loss of 300 million dollars was suffered in the United States.

In the past, several methods have been used in attempts to control coccidiosis. Prior to the advent

of chemotherapeutic agents, improved sanitation using disinfectants, together with the mechanical removal of litter, was the main method employed; sufficient oocysts, however, usually remained to transmit the disease.

The introduction of coccidiostatic agents in the feed or drinking water, in addition to good management, resulted in some success at disease control. Such agents have been found to suffer from a drop in effectiveness over the years, due partly to the development of drug resistant strains of coccidia. Furthermore, several chemotherapeutic agents have been found to leave residues in the meat, making it unsuitable for consumption.

Attempts have been made to control the disease immunologically by administering to chickens a live vaccine comprising oocysts from all seven species of *Eimeria*, the oocysts administered being from precocious lines. Such precocious lines are obtained by inoculating chickens with a wild population of an *Eimeria* species and collecting the very first parasites that are excreted as a result of the infection. The collected parasites are put back into chickens and the cycle is repeated several times. Eventually a precocious line of parasite is produced which has fewer cycles of asexual reproduction in the gut. Thus such lines retain their immunogenicity, whilst producing fewer parasites in the gut with less consequential damage being caused to the host chicken.

The disadvantage of this type of vaccine is that it is expensive to produce because of the necessity of producing it in live chickens and its lower reproductive potential.

The advent of genetic engineering has provided new methods for producing effective vaccines. Using these methods, the DNA coding for the antigenic proteins of some pathogenic microorganisms has been cloned into such host microorganisms as *Escherichia coli* or *Salmonella* spec., with the result that the protein has been expressed at sufficiently high levels such that it can be incorporated into a vaccine. The advantage of proteins produced in this way is that they are noninfectious and are relatively cheap to produce. In this way, vaccines have been prepared against a number of viruses such as hepatitis, herpes simplex and foot and mouth disease.

Attempts have been made to genetically engineer a coccidiosis vaccine. European patent application No. 337 589 describes the isolation of a Group B *Eimeria tenella* protein and its insertion into a novel expression vector which, in turn, has been used to transform appropriate hosts. Patent Cooperation Treaty Application WO 92/04461 describes the construction of a microorganism that produces an antigenic protein using either the "mRNA route" or the "nuclear DNA route". In this way, certain antigens from *E. tenella* and *E. maxima* were prepared and sequenced. Taking this type of route to prepare antigens for incorporation into a vaccine relies only upon selecting antigens which could induce antibodies in an heterologous species. This approach does not necessarily end up with selecting the most protective antigen.

From H.S. Lillehoj (Vet. Immunol. Immunopath., 13, 321-330, 1986) it can be conceived that development of protective immunity in chickens infected with coccidia may be due to the development of a species-specific T cell response.

It has now been found that a very immunogenic protein can be isolated from the 42hr developmental stage of *Eimeria* schizonts. Surprisingly, this protein is found intracellularly in *Eimeria* and it appears to contain high sequence homology with known heterologous lactate dehydrogenases (LDH).

Thus, the invention provides a protein having one or more immunoreactive and/or antigenic determinants of *Eimeria* lactate dehydrogenase, which has a monomeric molecular weight of about 37 kD.

More specifically the lactate hydrogenase is derived from *Eimeria acervulina*.

According to a second aspect of the invention, there is provided a nucleic acid sequence encoding all or a substantial part, in particular the immunologically active part, of a purified *Eimeria* lactate dehydrogenase. Such a nucleic acid sequence may be operatively linked to expression control sequences resulting in a recombinant nucleic acid molecule which, when inserted into a suitable vector, results in a recombinant vector capable of expressing the nucleic acid sequence.

Such a recombinant vector, or nucleic acid sequence as defined above, may be used to transform a suitable host cell or organism. Such a transformed host cell or organism may, in turn, be used to produce the stimulatory protein for incorporation into a vaccine

for the protection of poultry against coccidiosis. Alternatively, the transformed host cell or organism may itself be incorporated into a vaccine.

In general, the term "protein" refers to a molecular chain of amino acids with biological activity. A protein is not of a specific length and can, if required, be modified *in vivo* or *in vitro*, by, for example, glycosylation, amidation, carboxylation or phosphorylation; thus, *inter alia*, peptides, oligopeptides and polypeptides are included within the definition.

More particularly, this invention provides proteins possessing LDH activity, or immunogenically active parts thereof, which have the amino acid sequence shown in SEQ ID NO. 2 and their biologically functional equivalents or variants.

The biologically functional equivalents or variants of the proteins specifically disclosed herein are proteins derived from the abovenoted amino acid sequences, for example by deletions, insertions and/or substitutions of one or more amino acids, but retain one or more immunogenic determinants of the *Eimeria* antigens, i.e. said variants have one or more epitopes capable of eliciting an immune response in a host animal.

It will be understood that, for the particular proteins embraced herein, natural variations can exist between individual *Eimeria* parasites or strains. These variations may be demonstrated by (an) amino acid difference(s) in the overall sequence or by deletions, substitutions, insertions, inversions or additions of (an) amino acid(s) in said sequence. Amino acid substitutions which do not essentially alter

biological and immunological activities, have been described, e.g. by Neurath et al in "The Proteins" Academic Press New York (1979). Amino acid replacements between related amino acids or replacements which have occurred frequently in evolution are, inter alia, Ser/Ala, Ser/Gly, Asp/Gly, Asp/Asn, Ile/Val (see Dayhof, M.D., Atlas of protein sequence and structure, Nat. Biomed. Res. Found., Washington D.C., 1978, vol. 5, suppl. 3). Other amino acid substitutions include Asp/Glu, Thr/Ser, Ala/Gly, Ala/Thr, Ser/Asn, Ala/Val, Thr/Phe, Ala/Pro, Lys/Arg, Leu/Ile, Leu/Val and Ala/Glu. Based on this information, Lipman and Pearson developed a method for rapid and sensitive protein comparison (Science, 227, 1435-1441, 1985) and determining the functional similarity between homologous proteins. Such amino acid substitutions of the exemplary embodiments of this invention are within the scope of the invention as long as the resulting proteins retain their immunoreactivity.

Furthermore, also immunogenic fragments of the proteins specifically disclosed herein or their functional variants are included in the present invention.

The term "fragment" as used herein means a DNA or amino acid sequence comprising a subsequence of the nucleic acid sequence or protein of the invention. Said fragment is or encodes a polypeptide having one or more immunogenic determinants of an *Eimeria* antigen. Methods for determining usable immunogenic polypeptide fragments are outlined below. Fragments can inter alia be produced by enzymatic cleavage of precursor molecules, using restriction endonucleases for the DNA and proteases for the polypeptides. Other methods include chemical synthesis of the fragments or

RECEIVED  
MAY 22 1986  
U.S. PATENT AND TRADEMARK OFFICE

the expression of polypeptide fragments by DNA fragments.

Suitable immunogenic polypeptide fragments of a protein according to the invention containing (an) epitope(s) can be found by means of the method described in Patent Application WO 86/06487, Geysen, H.M. et al. (Proc. Natl. Acad. Sci. 81, 3998-4002, 1984), Geysen, H.M. et al. (J. Immunol. Meth. 102, 259-274, 1987) based on the so-called pepscan method, wherein a series of partially overlapping peptides corresponding with partial sequences of the complete polypeptide under consideration, are synthesized and their reactivity with antibodies is investigated.

In addition, a number of regions of the polypeptide, with the stated amino acid sequence, can be designated epitopes on the basis of theoretical considerations and structural agreement with epitopes which are now known. The determination of these regions is based on a combination of the hydrophilicity criteria according to Hopp and Woods (Proc. Natl. Acad. Sci. 78, 3824-3828, 1981) and the secondary structure aspects according to Chou and Fasman (Advances in Enzymology 47, 45-148, 1987).

T-cell epitopes which may be necessary can likewise be derived on theoretical grounds, e.g. with the aid of Berzofsky's amphiphilicity criterion (Science 235, 1059-62, 1987).

The invention further provides isolated and purified nucleic acid sequences encoding the above mentioned proteins of *Eimeria*. One of these nucleic acid sequences is shown in SEQ. ID. NO. 1. It is well known in the art that the degeneracy of the genetic code permits substitution of bases in the codon resulting in another codon but still coding for the same amino acid, e.g. the codon for the amino acid glutamic acid is both GAT and GAA. Consequently, it is

RECORDED IN 35MM  
SEARCHED  
INDEXED  
SERIALIZED  
FILED

clear that, for the expression of a protein with the amino acid sequence shown in SEQ. ID. NO. 2, the nucleic acid sequence may have a codon composition different from the nucleic acid sequence shown in SEQ. ID. NO. 1.

A nucleic acid sequence according to the present invention may be isolated from an *Eimeria* strain and multiplied by recombinant DNA techniques including polymerase chain reaction (PCR) technology or may be chemically synthesized in vitro by techniques known in the art.

A nucleic acid sequence according to the invention can be ligated to various replication effecting DNA sequences with which it is not associated, or linked in nature, resulting in a so-called recombinant vector which can be used for the transformation of a suitable host. Useful recombinant vectors are preferably derived from plasmids, bacteriophages, cosmids or viruses.

Specific vectors or cloning vehicles which can be used to clone nucleic acid sequences according to the invention are known in the art and include inter alia plasmid vectors such as pBR322, the various pUC, pGEM and Bluescript plasmids; bacteriophages, e.g.  $\lambda$ gt-Wes, Charon 28 and the M13 derived phages or viral vectors such as SV40, adenovirus or polyoma virus (see also Rodriguez, R.L. and D.T. Denhardt, ed., *Vectors: A survey of molecular cloning vectors and their uses*, Butterworths, 1988; Lenstra, J.A. et al., *Arch. Virol.*, 110, 1-24, 1990). The methods to be used for the construction of a recombinant vector according to the invention are known to those of ordinary skill in the art and are inter alia set forth in Maniatis, T.

et al. (Molecular Cloning A Laboratory Manual, second edition; Cold Spring Harbor Laboratory, 1989).

For example, the insertion of the nucleic acid sequence according to the invention into a cloning vector can easily be achieved when both the genes and the desired cloning vehicle have been cut with the same restriction enzyme(s) as complementary DNA termini are thereby produced.

Alternatively, it may be necessary to modify the restriction sites that are produced into blunt ends either by digesting the single-stranded DNA or by filling in the single-stranded termini with an appropriate DNA polymerase. Subsequently, blunt end ligation with an enzyme such as T4 DNA ligase may be carried out.

If desired, any restriction site may be produced by ligating linkers onto the DNA termini. Such linkers may comprise specific oligonucleotide sequences that encode restriction site sequences. The restriction enzyme cleaved vector and nucleic acid sequence may also be modified by homopolymeric tailing.

"Transformation", as used herein, refers to the introduction of an heterologous nucleic acid sequence into a host cell, irrespective of the method used, for example direct uptake or transduction. The heterologous nucleic acid sequence may be maintained through autonomous replication or, alternatively, may be integrated into the host genome. If desired, the recombinant vectors are provided with appropriate control sequences compatible with the designated host. These sequences can regulate the expression of the inserted nucleic acid sequence. In addition to

microorganisms, cell cultures derived from multicellular organisms may also be used as hosts.

The recombinant vectors according to the invention preferably contain one or more marker activities that may be used to select for desired transformants, such as ampicillin and tetracycline resistance in pBR322, ampicillin resistance and  $\alpha$ -peptide of  $\beta$ -galactosidase in pUC8.

A suitable host cell is a microorganism or cell which can be transformed by a nucleic acid sequence encoding a polypeptide or by a recombinant vector comprising such a nucleic acid sequence, and which can, if desired, be used to express said polypeptide encoded by said nucleic acid sequence. The host cell can be of prokaryotic origin, e.g. bacteria such as Escherichia coli, Bacillus subtilis and Pseudomonas species; or of eukaryotic origin such as yeasts, e.g. Saccharomyces cerevisiae or higher eukaryotic cells such as insect, plant or mammalian cells, including HeLa cells and Chinese hamster ovary (CHO) cells. Insect cells include the Sf9 cell line of Spodoptera frugiperda (Luckow et al., Biotechnology 6, 47-55, 1988). Information with respect to the cloning and expression of the nucleic acid sequence of the present invention in eukaryotic cloning systems can be found in Esser, K. et al. (Plasmids of Eukaryotes, Springer-Verlag, 1986).

In general, prokaryotes are preferred for the construction of the recombinant vectors useful in the present invention. *E.coli* K12 strains are particularly useful, especially DH5a or MC1061 strains.

For expression, nucleic acid sequences of the present invention are introduced into an expression

卷之三

vector, i.e. said sequences are operably linked to expression control sequences. Such control sequences may comprise promotors, enhancers, operators, inducers, ribosome binding sites etc. Therefore, the present invention provides a recombinant vector comprising a nucleic acid sequence encoding an *Eimeria* protein identified above operably linked to expression control sequences, which is capable of expressing the DNA sequences contained therein in (a) transformed host cell(s).

It should be understood, of course, that the nucleotide sequences inserted at the selected site of the cloning vector may include nucleotides which are not part of the actual structural gene for the desired polypeptide, or may include only a fragment of the complete structural gene for the desired protein as long as the transformed host will produce a polypeptide having at least one or more immunogenic determinants of an *Eimeria* protein antigen.

When the host cells are bacteria, useful expression control sequences which may be used include the Trp promotor and operator (Goeddel, et al., *Nucl. Acids Res.*, 8, 4057, 1980); the lac promotor and operator (Chang, et al., *Nature*, 275, 615, 1978); the outer membrane protein promotor (Nakamura, K. and Inouge, M., *EMBO J.*, 1, 771-775, 1982); the bacteriophage lambda promotors and operators (Remaut, E. et al., *Nucl. Acids Res.*, 11, 4677-4688, 1983); the  $\alpha$ -amylase (*B. subtilis*) promotor and operator, termination sequences and other expression enhancement and control sequences compatible with the selected host cell. When the host cell is yeast, illustrative useful expression control sequences include, e.g.,  $\alpha$ -mating factor. For insect cells the polyhedrin or p10 promotors of baculoviruses can be used (Smith, G.E. et al., *Mol.*

SEARCHED  
INDEXED  
SERIALIZED  
FILED

Cell. Biol. 3, 2156-65, 1983). When the host cell is of mammalian origin illustrative useful expression control sequences include the SV-40 promotor (Berman, P.W. et al., Science, 222, 524-527, 1983) or the metallothionein promotor (Brinster, R.L., Nature, 296, 39-42, 1982) or a heat shock promotor (Voellmy et al., Proc. Natl. Acad. Sci. USA, 82, 4949-53, 1985). Alternatively, expression control sequences present in *Eimeria* may also be applied. For maximizing gene expression, see also Roberts and Lauer (Methods in Enzymology, 68, 473, 1979).

Therefore, the invention also comprises (a) host cell(s) containing a nucleic acid sequence or a recombinant nucleic acid molecule or a recombinant vector described above, capable of producing the *Eimeria* protein by expression of the nucleic acid sequence.

Immunization of poultry against *Eimeria* infection can be achieved by administering to the birds a protein according to the invention in an immunologically relevant context as a so-called subunit vaccine. The subunit vaccine according to the invention may comprise a protein in a pure form, optionally in the presence of a pharmaceutically acceptable carrier. The protein can optionally be covalently bonded to a non-related protein, which can be of advantage in the purification of the fusion product. Examples are  $\beta$ -galactosidase, protein A, prochymosine, blood clotting factor Xa, etc.

In some cases the ability to raise protective immunity using these proteins *per se* may be low. Small fragments are preferably conjugated to carrier molecules in order to raise their immunogenicity.

Suitable carriers for this purpose are macromolecules, such as natural polymers (proteins like key hole limpet hemocyanin, albumin, toxins), synthetic polymers like polyamino acids (polylysine, polyalanine), or micelles of amphiphilic compounds like saponins. Alternatively these fragments may be provided as polymers thereof, preferably linear polymers.

If required, the proteins according to the invention which are to be used in a vaccine can be modified *in vitro* or *in vivo*, for example by glycosylation, acylation, amidation, carboxylation or phosphorylation.

A newly developed vaccine version is a vaccine in which the DNA coding for the protein of the invention is administered in a pharmaceutically acceptable form, for instance in the form of "bullets", which can be shot into the tissue. This naked DNA can be used as vaccine provided it is presented in a plasmid or in combination with suitable eukaryotic promoter sequences such as those from SV40 virus. In this way one can achieve the introduction of this DNA into the genomic DNA, thus ensuring the expression of the antigen *in situ*.

An alternative to subunit vaccines is live vaccines. A nucleic acid sequence according to the invention is introduced by recombinant DNA techniques into a microorganism (e.g. a bacterium or virus) in such a way that the recombinant microorganism is still able to replicate, thereby expressing a polypeptide coded by the inserted nucleic acid sequence and eliciting an immune response in the infected host bird.

A preferred embodiment of the present invention is a recombinant vector virus comprising an heterologous nucleic acid sequence described above, capable of expressing the DNA sequence in (a) host cell(s) or host bird infected with the recombinant vector virus. The term "heterologous" indicates that the nucleic acid sequence according to the invention is not normally present in nature in the vector virus.

Furthermore, the invention also comprises (a) host cell(s) or cell culture infected with the recombinant vector virus, capable of producing the *Eimeria* protein by expression of the nucleic acid sequence.

For example the well known technique of *in vivo* homologous recombination can be used to introduce an heterologous nucleic acid sequence according to the invention into the genome of the vector virus.

First, a DNA fragment corresponding with an insertion region of the vector genome, i.e. a region which can be used for the incorporation of an heterologous sequence without disrupting essential functions of the vector such as those necessary for infection or replication, is inserted into a cloning vector according to standard recDNA techniques. Insertion-regions have been reported for a large number of microorganisms (e.g. EP 80,806, EP 110,385, EP 83,286, EP 314,569, WO 88/02022, WO 88/07088, US 4,769,330 and US 4,722,848).

Second, if desired, a deletion can be introduced into the insertion region present in the recombinant vector molecule obtained from the first step. This can be achieved for example by appropriate exonuclease III digestion or restriction enzyme treatment of the recombinant vector molecule from the first step.

Third, the heterologous nucleic acid sequence is inserted into the insertion-region present in the recombinant vector of the first step or in place of the DNA deleted from said recombinant vector. The insertion region DNA sequence should be of appropriate length as to allow homologous recombination with the vector genome to occur. Thereafter, suitable cells can be infected with wild-type vector virus or transformed with vector genomic DNA in the presence of the recombinant vector containing the insertion flanked by appropriate vector DNA sequences whereby recombination occurs between the corresponding regions in the recombinant vector and the vector genome. Recombinant vector progeny can now be produced in cell culture and can be selected for example genotypically or phenotypically, e.g. by hybridization, detecting enzyme activity encoded by a gene co-integrated along with the heterologous nucleic acid sequence, or detecting the antigenic heterologous polypeptide expressed by the recombinant vector immunologically.

Next, this recombinant microorganisms can be administered to poultry for immunization whereafter it maintains itself for some time, or even replicates in the body of the inoculated animal, expressing in vivo a polypeptide coded for by the inserted nucleic acid sequence according to the invention resulting in the stimulation of the immune system of the inoculated animal. Suitable vectors for the incorporation of a nucleic acid sequence according to the invention can be derived from viruses such as pox viruses, e.g. vaccinia virus (EP 110,385, EP 83,286, US 4,769,330 and US 4,722 848) or fowl pox virus (WO 88/02022), herpes viruses such as HVT (WO 88/07088) or Marek's Disease virus, adeno virus or influenza virus, or bacteria such as E. coli or specific Salmonella

species. With recombinant microorganisms of this type, the polypeptide synthesized in the host animal can be exposed as a surface antigen. In this context fusion of the polypeptide with OMP proteins, or pilus proteins of for example *E. coli* or synthetic provision of signal and anchor sequences which are recognized by the organism are conceivable. It is also possible that the *Eimeria* polypeptide, if desired as part of a larger whole, is released inside the animal to be immunized. In all of these cases it is also possible that one or more immunogenic products will find expression which generate protection against various pathogens and/or against various antigens of a given pathogen.

A vector vaccine according to the invention can be prepared by culturing a recombinant bacterium or a host cell infected with a recombinant vector comprising a nucleic acid sequence according to the invention, whereafter recombinant bacteria or vector containing cells and/or recombinant vector viruses grown in the cells can be collected, optionally in a pure form, and formed into a vaccine optionally in a lyophilised form.

Host cells transformed with a recombinant vector according to the invention can also be cultured under conditions which are favourable for the expression of a polypeptide coded by said nucleic acid sequence. Vaccines may be prepared using samples of the crude culture, host cell lysates or host cell extracts, although in another embodiment more purified polypeptides according to the invention are formed into a vaccine, depending on its intended use. In order to purify the polypeptides produced, host cells transformed with a recombinant vector according to the invention are cultured in an adequate volume and the

polypeptides produced are isolated from such cells, or from the medium if the protein is excreted. Polypeptides excreted into the medium can be isolated and purified by standard techniques, e.g. salt fractionation, centrifugation, ultrafiltration, chromatography, gel filtration or immuno affinity chromatography, whereas intra cellular polypeptides can be isolated by first collecting said cells, disrupting the cells, for example by sonication or by other mechanically disruptive means such as French press, followed by separation of the polypeptides from the other intracellular components and forming the polypeptides into a vaccine. Cell disruption could also be achieved by chemical (e.g. EDTA or detergents such as Triton X114) or enzymatic means, such as lysozyme digestion.

Antibodies or antiserum directed against a polypeptide according to the invention have a potential use in passive immunotherapy, diagnostic immunoassays and generation of anti-idiotypic antibodies.

The *Eimeria* proteins as characterized above can be used to produce antibodies, both polyclonal, monospecific and monoclonal. If polyclonal antibodies are desired, techniques for producing and processing polyclonal sera are known in the art (e.g. Mayer and Walter. eds, Immunochemical Methods in Cell and Molecular Biology, Academic Press, London, 1987). Monospecific antibodies to an immunogen can be affinity purified from polyspecific antisera by a modification of the method of Hall et al. (Nature, 311, 379-387, 1984). Monospecific antibody, as used herein, is defined as a single antibody species or multiple antibody species with homogeneous binding characteristics for the relevant antigen. Homogeneous

binding, as used herein, refers to the ability of the antibody species to bind to a specific antigen or epitope.

Monoclonal antibodies, reactive against the *Eimeria* proteins according to the present invention, can be prepared by immunizing inbred mice by techniques known in the art (Köhler and Milstein, *Nature*, 256, 495-497, 1975). Hybridoma cells are selected by growth in hypoxanthine, thymidine and aminopterin in an appropriate cell culture medium such as Dulbecco's modified Eagle's medium. Antibody producing hybridomas are cloned, preferably using the soft agar technique of MacPherson, (*Soft Agar Techniques, Tissue Culture Methods and Applications*, Kruse and Paterson, eds., Academic Press, 276, 1973). Discrete colonies are transferred into individual wells of culture plates for cultivation in an appropriate culture medium. Antibody producing cells are identified by screening with the appropriate immunogen. Immunogen positive hybridoma cells are maintained by techniques known in the art. Specific anti-monoclonal antibodies are produced by cultivating the hybridomas *in vitro* or preparing ascites fluid in mice following hybridoma injection by procedures known in the art.

Anti-idiotypic antibodies are immunoglobulins which carry an "internal image" of the antigen of the pathogen against which protection is desired and can be used as an immunogen in a vaccine (Dreesman et al., *J. Infect. Disease*, 151, 761, 1985). Techniques for raising anti-idiotypic antibodies are known in the art (MacNamara et al., *Science*, 226, 1325, 1984).

The vaccine according to the invention can be administered in a conventional active immunization scheme: single or repeated administration in a manner compatible with the dosage formulation, and in such amount as will be prophylactically effective, i.e. the amount of immunizing antigen or recombinant microorganism capable of expressing said antigen that will induce immunity in poultry against challenge by virulent *Eimeria* parasites. Immunity is defined as the induction of a significant level of protection in a population of chickens after vaccination compared to an unvaccinated group.

Next to an increase in protection a vaccine comprising the polypeptide of the invention will also reduce the number of oocysts shedded by the infected animals. Normally, the shedded oocysts will infect other animals in the flock. A decrease in the number of oocysts shedded will then also give a decrease in the number of animals which is subsequently infected and also a decrease in the number of oocysts shedded will give rise to a lesser infective load.

Furthermore, even without effect on the parasite itself, a vaccine can decrease the incidence of disease. This is especially so when the symptoms of the disease are caused by products released by the parasite. Vaccines directed against such products alleviate the symptoms without attacking the parasite.

For live viral vector vaccines the dose rate per chicken may range from  $10^5$ - $10^8$  pfu. A typical subunit vaccine according to the invention comprises 1  $\mu$ g - 1 mg of the protein according to the invention. Such vaccines can be administered intradermally, subcutaneously, intramuscularly, intraperitoneally, intravenously, orally or intranasally.

Additionally the vaccine may also contain an aqueous medium or a water containing suspension, often mixed with other constituents in order to increase the activity and/or the shelf life. These constituents may be salts, pH buffers, stabilizers (such as skimmed milk or casein hydrolysate), emulsifiers, adjuvants to improve the immune response (e.g. oils, muramyl dipeptide, aluminium hydroxide, saponin, polyanions and amphipatic substances) and preservatives.

A vaccine comprising the polypeptide of the invention may also comprise other immunogenic proteins of *E. maxima* or immunogenic proteins of other *Eimeria* species. Such a combination vaccine will decrease the parasitic load in a flock of poultry and will increase the level of protection against coccidiosis.

It is clear that a vaccine according to the invention may also contain immunogens related to other pathogens of poultry, or may contain nucleic acid sequences encoding these immunogens, like antigens of Marek's Disease virus (MDV), Newcastle Disease virus (NDV), Infectious Bronchitis virus (IBV), Chicken Anemia Agent (CAA), Reo virus, Avian Retro virus, Fowl Adeno virus, Turkey Rhinotracheitis virus or E. coli to produce a multivalent vaccine.

The invention is illustrated by the following examples:

EXAMPLE 1Handling of parasites

*Eimeria acervulina* (Houghton strain) and *Eimeria tenella* (Weybridge strain) parasites were collected after deliberate infection of chickens reared in the absence of coccidia. *E. acervulina* oocysts were isolated from fecal material on days 4 and 5 post-infection (p.i.). *E. tenella* oocysts were harvested from the ceca on day 7 p.i..

The oocysts were sporulated with strong aeration at 30°C for 7 hours, resulting in partially sporulated oocysts. Release of sporocysts and sporozoites of 48 hr sporulated oocysts was performed as described earlier in A.N. Vermeulen et al. FEMS Microbiological Letters 110, (1993), 223-230.

To obtain *E. acervulina* intra-cellular stages, chickens were infected at 5 weeks with  $10^8$  sporulated *E. acervulina* oocysts. Intracellular parasites were harvested from the duodenum after 42 hours. Hereto chickens were exsanguinated 42hr post inoculation and duodenum was removed from the stomach to Meckel's diverticulum. The tissue was washed and cut into small pieces of approximately 1 cm<sup>3</sup>. The pieces were suspended in calcium/magnesium free Hanks BSS containing 10 mg/ml glucose (CMF-Hanks). Epithelial cells were released from the matrix by ~10 min incubation in EDTA (2 mM EDTA in CMF Hanks at 35-37°C). Supernatants of four incubations were pooled and centrifuged 10 min at 750g, which pelleted the cells. The intracellular parasites (further called "schizonts", although also trophozoites were present) were subsequently released from the host cells by saponin lysis (15 min in 0.1% saponin in CMF-Hanks at roomtemperature) and mechanical shearing.

G547600 "G547600" G547600 G547600

The schizonts were pelleted and separated from host material after centrifugation through 45% Percoll (Pharmacia Fine Chemicals) (20 min, 700g, 4°C). Dry pellets of schizonts were stored at -70°C until further use.

#### Triton X114 extraction

Triton X114 extractions were carried out to obtain the hydrophilic protein fraction of schizonts. The procedure used was described earlier by C. Bordier (1981) *Journal of Biological Chemistry*, vol. 256 no. 4 (feb) pp. 1604-1607.

$10^8$  to  $10^9$  *E acervulina* schizonts per ml of TBS (10 mM Tris-HCl, 150 mM NaCl pH7.4) were sonified  $\pm 3 \times 20$  sec. on ice with the microtip (Branson sonifier, position 7). PMSF (final concentration 1 mM) and DNase/RNase (final concentration for both 0.02 mg/ml) was added (DNase/RNase stock: 2 mg/ml DNase, 2 mg/ml RNase in 5 mM MgCl<sub>2</sub>).

Precondensed TritonX114 was added to the sonified schizonts in suspension to a final concentration of 10% (v/v) and mixed well to dissolve the proteins. The non-extractable material was pelleted by centrifugation 20 min 12,000g at 4°C. The soluble fraction was layered over a sucrose cushion (6% sucrose, 0.06% (v/v) TX114 in TBS), incubated 10 min 40°C and spun 10 min 400g at roomtemperature. The hydrophilic fraction was extracted again by the same procedure.

The hydrophilic fractions were stored at -70°C until further use. Total protein concentration was determined using the BCA (Pierce Chemicals) assay.

### Prep-cell fractionation

Hydrophilic proteins were further separated with respect to their relative molecular mass on SDS-PAGE under reducing conditions in the Laemmli buffer system. Hereto we made use of preparative electrophoresis in the so-called Prepcell.

#### Materials:

Prep cell apparatus (Biorad Labs) with Prep cell column (37mm ID)

Dialyse membrane for Prep cell (cut off 6kD)

Powersupply (EPS 600 Pharmacia)

Reducing sample buffer: 62.5 mM Tris-HCl pH 6.8; 10% glycerol; 2% SDS; 0.01% bromo phenol blue (Merck); 0.13 M DTT (dithiothreitol, Merck)

Electrophoresis buffer/elution buffer: 25 mM Tris, 192 mM Glycine, 0.1% SDS pH8.6

#### Method and results:

All procedures were performed at 4°C. For the fractionation of the hydrophilic proteins a 4% stacking/9% separating gel (polyacrylamide) was used in the 37mm tube (filled to 6cm) of the Prepcell according to the manufacturers protocol, but with the addition of 0.1% SDS.

The hydrophilic phase of TX114 extractions kept at -70°C was thawed and the hydrophilic proteins (about 8mg per run) were diluted in reducing sample buffer (total volume was  $\pm$  6 ml), boiled 3 min 100°C, and were loaded on the surface of the 4% stacking gel using a narrow tube affixed to a syringe.

The Prepcell was connected to the powersupply and electrophoresis was started at 40mA, 500V max.

The collection of fractions (fraction volume  $\pm$ 2.5-3ml; flow 0.6ml/min) started after about 6 hours, when the tracking dye eluted from the cell. Fractions were collected overnight ( $\pm$ 100 fractions) in plastic 3.5ml tubes (Sarstedt).

Samples of the fractions were taken for analysis by SDS-PAGE and Western Blotting. Fractions were stored at -70°C.

This purification method resulted in fractions containing almost pure proteins as follows from analyses shown below.

#### Amino acid sequencing

Selected fractions of Prepcellrun COC9314612 containing an almost pure band around Mr=37k (designated as EASC2) were pooled, concentrated by acetoneprecipitation and run on a 12% PAAgel. The gel was shortly stained with a non-denaturing Coomassie Brilliant Blue staining protocol: staining: 20 min at ambient temperature in 0.2% CBB in 20% methanol/0.5% acetic acid. Destaining: 60 min in 30% methanol.

The staining 37kD band was cut out. Internal amino acid sequencing was performed on a selected HPLC-purified peptide of a trypsin digest of the EASC2, all performed by Eurosequence BV Groningen The Netherlands.

The amino-acid sequence of the tryptic peptide was GWIKQEEVDDIVQK (see SEQ.ID.No:2 amino acids 212-225).

This coding sequence for this peptide was also detected after DNA sequencing of the clone.

EXAMPLE 2Preparation of monospecific antibodies in rabbits

Prevaccination sera of SPF rabbits were screened on western blotted *E. acervulina* antigens of different developmental stages and on a blot of *E. coli* proteins. 'Negative' rabbits were selected for the raising of antibodies.

Fractions of Prepcellruns containing EASC2 (37kD) were selected by SDS-PAGE, pooled and concentrated ( $\pm$  3x) with an Amiconcell (YM10 filter) to 3.5ml.

The rabbit was twice immunized with concentrated antigen in GNE (8x 0.25ml i.c.; 1ml i.p.) with an interval of 4 weeks. Two weeks after the second immunisation the rabbit was bled and sera were tested on western blots of *Eimeria acervulina* en *tenella* sporozoites and schizonts 42hr. Figure 1 shows the result of the immunodetection of the monospecific antiserum on sporozoite antigens of both species. It appeared that the antibodies recognised a parasite product of about 37kD in both *E. acervulina* (Lane A1) and *E. tenella* (Lane B1). Control sera of the same rabbit prior to immunization did not recognise these bands (Lanes A/B2). The protein is also present in schizont stages of the two species (not shown).

EXAMPLE 3Vaccination of chickens with E.acervulina TX114 hydrophilic fraction and EASC2

The TX114 hydrophilic phase of schizont material was separated and dialysed extensively against 0.01M PBS pH 7.3 at 4°C.

Selected fractions containing the EASC2 37kD protein were dialysed extensively against 3 x 5 liter 0.01 M PBS pH 7.3 at 4°C.

The concentration of protein in the vaccine preparations was estimated by staining different concentrations of sample with CBB after SDS-PAGE and comparing the intensity of the staining with a reference sample of BSA.

The volumes were corrected to obtain  $\pm$  5  $\mu$ g protein/dose for the purified protein and about 15  $\mu$ g/dose for the total hydrophilic fraction.

These were stored as aliquotted volumes for priming and booster vaccination at -70°C. Frozen vaccine preparations were thawed.

To every 15 ml of vaccine 3.2 mg Quil A Superfos Biosector was added as adjuvant in a volume of 1 ml 0.01 M PBS pH 7.3.

Vaccine was mixed well by vortexing and injected in 4-6 week old coccidia-free White Leghorn chickens in 0.75 ml given subcutaneously.

The vaccine contained 150  $\mu$ g Quil A/dose.

Figure 2 shows a Coomassie BB stained SDS-PAGE of the EASC2 (Lane 1) and 42hr TX114 hydrophilic fraction (Lane 2) injected into the chickens as vaccine.

Four weeks after priming birds were boosted with the same dose via the same route. The booster-vaccine was prepared freshly from the frozen antigen stock.

Control chickens were inoculated with 150  $\mu$ g Quil A/dose in PBS. Each group comprised 14 chickens.

Eleven days after the boosting vaccination all chickens were inoculated orally with 240 sporulated oocysts of *Eimeria acervulina* H in 1 ml of 15% sucrose in water.

Chickens were placed in cages 2 birds per cage. Oocyst output was assessed in fecal samples taken from days 4 to 8 after challenge.

Table 2 shows the results of this experiment. Oocyst output is expressed as % oocysts from the output in the control animals.

Statistical evaluation of the data was performed on the LOG of the number of oocysts using Student's T-test or Mann-Whitney 's test if data distribution was not normal.

When  $p<0.05$  the difference was regarded significant.

This table shows that both the TX114 fraction and the EASC2 prep cell purified fraction induce a statistically significant reduction ( $p<0.05$ ) in oocyst output after challenge.

Prep cell purification seemed to improve the protection induced by the TX114 vaccine.

Table 2. Oocyst output in percents from control and statistical value of difference

Immunogen	% oocyst output from control $\pm$ S.D.	p value different from control
EASC2 prep cell pure $\pm$ 5 $\mu$ g/dose	72 $\pm$ 30	p=0.01
Hydrophilic TX114 proteins of Schizonts $\pm$ 15 $\mu$ g/dose	84 $\pm$ 17	p=0.02

In another experiment in which only total extracts of 42 hr schizonts were used as vaccine no significant oocyst reduction could be induced (results not shown).

In a second experiment prepcell purified EASC2 was used in two different concentrations of 0.2 and 2  $\mu\text{g}/\text{dose}$ . Following the same protocol for immunization and challenge, protection was measured in ten chickens per group as reduction of oocyst output compared to the group inoculated with PBS/QuilA.

Table 3 summarises the average percentual oocyst output of the control for the two EASC2 vaccinated groups. This table demonstrates that the EASC2 protected in a dose dependent manner showing a statistically significant difference at a dose of 2  $\mu\text{g}/\text{dose}$ .

Table 3. Oocyst output in percents from control and statistical value of difference

Group	% oocysts $\pm$ S.D. (control output=100%)	significance of difference from control (p-value)
EASC2/Quil A 2 $\mu\text{g}/\text{dose}$	64.0 $\pm$ 22	0.008
EASC2/Quil A 0.2 $\mu\text{g}/\text{dose}$	90.2 $\pm$ 27	NOT SIGNIFICANT

EXAMPLE 4Immunological stimulation after vaccination with EASC2 or TX114 hydrophilic proteins.

In both protection experiments- mentioned above chickens were assayed for stimulation of immunological parameters such as T-lymphocyte proliferation and serum antibodies.

Serum antibodies

Antibodies recognising the vaccine constituents were only detected in sera from the groups vaccinated with the 42hr TX114-hydrophilic fraction and not the group vaccinated with the purified EASC2.

Lymphocyte proliferation

Lymphocyte proliferation after antigenic stimulus was tested in a lymphocyte stimulation test (LST).

Method:

Prior to challenge peripheral bloodcells were taken from all chickens of each group.

Peripheral blood leucocytes (PBL) were isolated by centrifugation 3 ml of the total blood for 7 min at 64g at ambient temperature. The buffy coat was collected in RPMI 1640 (Dutch modification) and washed two times. Cell concentration was adjusted to  $1 \times 10^7$  cells per ml in RPMI 1640. The RPMI 1640 (Dutch modification) used was supplemented with sodium pyruvate (1 mM), Glutamine (2 mM), penicillin 200 U/ml and streptomycin 200  $\mu$ g/ml.

96 well round-bottom tissue culture plates were seeded with 0.05 ml cell suspension with 3.0% chicken serum (Gibco BRL), 0.05 ml "stimulating antigen" suspension and 0.05 ml RPMI 1640 , cultured for 64 hr at 41°C under 5% CO<sub>2</sub> atmosphere. Subsequently 18.5 kBq

3-H-Thymidine (Amersham Beckenham U.K.) was added per well and 8 hrs later the cells were harvested on a glass-fibre filter (Skatron Norway Bluemat) using a 96 well Cell Harvester (Skatron Norway). The filters were saturated with scintillation fluid (LKB BetaScint) and counted in a Betaplate 1205 (Pharmacia / LKB Sweden).

As "stimulating antigen" *E.acervulina* schizonts were used, which were sonicated using a microtip-equipped Branson sonifier at position 6 for 3x20 seconds with intermediate cooling and store at -70°C. The antigens were thawed before use and diluted to meet the concentration used for the stimulation. PBL of all groups were stimulated with  $3 \cdot 10^5$  *E. acervulina* schizonts.

Statistical evaluation was performed using Student's T-test on the LOG of the Stimulation Index (SI) (the number of counts per min (cpm) of the stimulated cultures divided by the cpm of the non-stimulated control). When  $p < 0.05$  the difference was regarded significant.

#### Results:

Table 4. shows the mean S.I. for the groups from both experiments described above. The first experiment in which EASC2 vaccine was compared with the TX114-hydrophilic fraction, and the second experiment dealing with the two dosages of the EASC2 vaccine.

It appeared that all antigens or dosages induced a significant positive T-cell response detectable in the peripheral blood at the time of challenge.

In both experiments, however, the higher dose of the prepcell pure EASC2 vaccine (2 or 5  $\mu$ g/dose) induced the very highest stimulation of T-cells. The ranking of the T-cell stimulation correlated with the reduction in oocyst output after challenge.

Table 4. Mean incorporation of  $^3\text{H}$ -Thymidine after stimulation with *E. acervulina* schizonts by PBL from groups immunised with the different vaccines, expressed as Stimulation Index (S.I)  $\pm$  Standard Error (SE).

Experiment	Group	$^3\text{H}$ -thymidine incorporation in S.I. $\pm$ SE
I	EASC2 5 $\mu\text{g}$	120 $\pm$ 47 @
	TX114 hydrophilic proteins	31 $\pm$ 12 @
	Placebo	6 $\pm$ 1
II	EASC2 2 $\mu\text{g}$	112 $\pm$ 28 @
	EASC2 0.2 $\mu\text{g}$	24 $\pm$ 4 @
	Placebo	2.3 $\pm$ 0.3

@) Significant from control group  $p < 0.001$

EXAMPLE 5

CLONING EXPERIMENTS

Sporulation of *E. acervulina* oocysts

A suspension of  $5 \times 10^8$  *E. acervulina* oocysts in 60 ml  $10^{-4}\text{M}$  sodium dithionite was centrifuged, after which the pellet was washed once with 100 ml sterile water. The cells were resuspended in 500 ml 2% potassium bichromate and then incubated under the influence of strong aeration for 7 hours at 30°C. The oocysts were then collected by centrifuging and washed three times with 200 ml sterile water.

Isolation of RNA

For the isolation of RNA (Pasternak J. et al., Mol. & Bioch. Par. 3, 133-142, 1981) the cell pellet was taken up into 2.8 ml of buffer containing 10 mM Tris acetate (pH7.6), 75 mM sodium acetate, 1% SDS, 2 mM EDTA, 0.2 mg/ml proteinase K and 10 mM vanadyl ribonucleoside complexes. The oocysts were destroyed by vortexing for 60 seconds (max) in the presence of 13 g glass beads ( $\phi$  0.5mm). 5 ml of phenol was added to the total extract and the mixture was vortexed for a further 60 seconds. After centrifuging, the supernatant liquor was pipetted off and again extracted with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1). RNA was precipitated after adding 2.5 volume ethanol and the resulting precipitate was dissolved in 800 ml Tris 10 mM, EDTA 0.1 mM pH 7.6 (T<sub>10</sub>E<sub>0.1</sub>), after which the product was extracted a further twice with an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) and twice with chloroform/isoamyl alcohol (24:1) and then precipitated with ethanol. PolyA<sup>+</sup>-RNA was isolated by means of oligo(dT)-cellulose chromatography (Maniatis T. et al.: Molecular Cloning. Cold Spring Harbor Laboratory, 1982). Approximately 100  $\mu$ g polyA<sup>+</sup>-RNA was isolated from 5\*10<sup>8</sup> oocysts.

cDNA synthesis

PolyA<sup>+</sup>-RNA was converted to cDNA by means of the enzyme MMLV reverse transcriptase. For this purpose 25  $\mu$ g polyA<sup>+</sup>-RNA was dissolved in 90 ml of water and denatured for 5 minutes at 20°C by adding mercury methyl hydroxide to 10 mM, after which  $\beta$ -Mercaptoethanol was added to 45 mM and the mixture incubated for a further 3 minutes at 20°C. The enzyme reaction was carried out in 190 ml buffer containing 4 mg oligo(dT)15, 150 U RNasin(R), 20 mM Tris (pH 7.6), 30 mM KCl, 4 mM dithiothreitol (DTT), 2 mM MgCl<sub>2</sub>, 1 mM of each dNTP and 3000 U MMLV reverse transcriptase.

The reaction was stopped after 1 hour incubation at 37°C by adding 10 ml 0.5 M EDTA. After extraction with an equal volume of phenol/chloroform/ isoamyl alcohol (25:24:1), the RNA/DNA hybrid was precipitated by adding ammonium acetate to 2 M and 2.5 volumes ethanol. The combined action of the enzymes DNA-polymerase I and RNase H (Gubbler U. et al., Gene 25, 263-269, 1983) results in the synthesis of the second string. The pellet was dissolved in 960  $\mu$ l of buffer containing 20 mM Tris (pH 7.6), 5 mM MgCl<sub>2</sub>, 100 mM (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.6 mM  $\beta$ -NAD, 16 U RNase H, 200 U DNA-polymeraseI and 20 U DNA-ligase (E.coli). The incubation time was 1 hour at 12°C and then 1 hour at 22°C, after which the reaction was stopped by adding an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) and precipitating with ethanol.

Before the cDNA was cloned in a vector suitable for this purpose it was first modified. cDNA (5  $\mu$ g) was dissolved in 100  $\mu$ l of buffer containing 30 mM sodium acetate (pH 5.6), 50 mM NaCl, 1 mM ZnSO<sub>4</sub> and 21 U Mung Bean Nuclease. After incubation for 30 minutes at 37°C the reaction was stopped by adding EDTA to 10 mM and Tris to 25 mM. After extraction with phenol/chloroform/isoamylalcohol (25:24:1) the mixture was desalinated over a Sephadex G50 column. The following were added to the eluate (125  $\mu$ l): Tris pH 7.6 to 50 mM, EDTA to 2.5 mM, DTT to 5 mM, S'-adenosylmethionine to 0.5 mM and 100 U EcoRI-methylase. After incubation for 30 minutes at 37°C, the reaction was stopped by heating for 15 minutes at 65°C, after which 1/10 volume of a solution containing Tris-HCl 100 mM, MgCl<sub>2</sub> 100 mM and NaCl 500 mM (pH7.5) was added, and, at the same time, each dNTP to 1 mM and 12.5 U Klenow DNA-polymerase. The reaction was stopped by adding an equal volume of phenol/chloroform/isoamyl alcohol (25:24:1) after incubating for 60 minutes at 22°C. The supernatant

liquor was precipitated after adding 350  $\mu$ l H<sub>2</sub>O and 50  $\mu$ l 3 M sodium acetate (pH 5.6) with 500  $\mu$ l isopropanol. After dissolving in 100 ml H<sub>2</sub>O, the pellet was desalinated over Sephadex G50 and the eluate precipitated with ethanol. After dissolving the pellet in 24  $\mu$ l H<sub>2</sub>O, ligation was carried out in 50  $\mu$ l by adding 2  $\mu$ g EcoRI linker, Tris-HCl(pH 8.0) to 30 mM, MgCl<sub>2</sub> to 10 mM, dithiothreitol to 10 mM, ATP to 1 mM, gelatin to 0.1 mg/ml and 10 U T4DNA-ligase. The reaction was stopped after 16 hours incubation at 4°C by heating (for 15 minutes at 70°C) after which cutting was carried out with restriction endonuclease EcoRI in 210  $\mu$ l buffer containing 100 mM Tris-HCl (pH 7.6), 50 mM NaCl, 10 mM MgCl<sub>2</sub>, 2.5 mM DTT and 500 U EcoRI. After 90 minutes incubation at 37°C, the reaction was stopped by means of extraction with an equal volume of phenol/chloroform/isoamylalcohol (25:24:1). The supernatant liquor was precipitated with 2.5 volume ethanol after adding sodium acetate (pH 5.6) to 300 mM cDNA and linkers were separated by means of a Biogel A15M column. The cDNA was precipitated with ethanol, after which the precipitate was dissolved in Tris-HCl 10 mM, EDTA 0.1 mM(pH 7.6). The cDNA molecules were then cloned in phage lambda ZAPII (Stratagene).

Screening of the cDNA bank ( $2 \times 10^5$  pfu) with antibodies directed against the EASC2 protein fraction of *E acervulina* schizonts revealed six positive phage clones. These antibodies were deluted 1:2000 with 1x Tris salt (Tris-HCl 10 mM, NaCl 150 mM, pH 8.0) + 0.05% Tween 20 + 10% Foetal Calf Serum (FCS) and incubated for two hours at room temperature(RT) with the filters. The filters were then washed 4 times, for 10 minutes each time, with 50 ml 1 x Tris salt + 0.05% Tween 20, each filter. For the second antibody incubation a conjugate of goat-anti-rabbit antibodies and alkaline phosphatase was used (diluted 1:7500 in

1x Tris salt + 0.05% Tween 20 + 10% FCS) and incubated for 30 minutes at RT, after which the filters were washed as described after the first antibody incubation. The colour reaction was carried out in Tris-HCl 100 mM, NaCl 100 mM, MgCl<sub>2</sub> 10 mM, (pH 9.6), in which 0.33 mg/ml Nitrobluetetrazolium and 0.17 mg/ml 5-bromo-4-chloro-3-indolyl phosphate were dissolved. The filters were evaluated after 30 minutes incubation at RT. The immunopositive clones were plaque-purified and rescued by means of in vivo excision, according to the protocol of the manufacturer (Stratagene). Plasmid DNA was isolated, from the resulting in vivo excision clones, for sequencing purposes according to standard protocols (Maniatis T., et al. *supra*). Partial sequence information showed all clones to be homologous, from the largest clone the nucleotide sequence was determined completely. This clone, designated pBLUE EASC2, contained an insert of 1566 bp.

Legend to the figures.

Fig. 1. Western blot of *E. acervulina* (A) and *E. tenella* (B) sporozoite proteins probed with antiserum raised against Prep cell purified EASC2 protein (Lane 1) or pre-immune control serum (Lane 2). Markers indicate molecular weight calibration in kD.

Fig. 2. Coomassie Brilliant Blue stained SDS-PAGE of Prep cell purified EASC2 protein (Lane 1) or TX114 hydrophilic fraction of *E. acervulina* 42hr schizonts (lane 2). Lane M contains molecular weight calibration markers in kD.

## SEQUENCE LISTING

## (1) GENERAL INFORMATION:

## (i) APPLICANT:

- (A) NAME: Akzo Nobel N.V.
- (B) STREET: Velperweg 76
- (C) CITY: Arnhem
- (E) COUNTRY: The Netherlands
- (F) POSTAL CODE (ZIP): 6824 BM
- (G) TELEPHONE: 04120-66204
- (H) TELEFAX: 04120-50592
- (I) TELEX: 37503 akpha nl

(ii) TITLE OF INVENTION: T cell stimulatory protein of *Eimeria*

(iii) NUMBER OF SEQUENCES: 2

## (iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

## (2) INFORMATION FOR SEQ ID NO: 1:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 1679 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: *Eimeria acervulina*
- (D) DEVELOPMENTAL STAGE: Schizont

(vii) IMMEDIATE SOURCE:

- (B) CLONE: EASC2\_1

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION:280..1269
- (D) OTHER INFORMATION:/function= "Eimeria lactate dehydrogenase"

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION:1..51
- (D) OTHER INFORMATION:/label= pBluescriptII

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION:1624..1679
- (D) OTHER INFORMATION:/label= pBluescriptII

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION:45..54
- (D) OTHER INFORMATION:/label= EcoRI-linker

(ix) FEATURE:

- (A) NAME/KEY: misc\_feature
- (B) LOCATION:1621..1630
- (D) OTHER INFORMATION:/label= EcoRI-linker

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GCCTGGCGG CCGCTCTAGA ACTAGTGGAT CCCCCGGGCT GCAGGAATTG	GGGTTTTTT	60
TTTTTTTCT ACACATTAAT ATTCTTCGTT TACGTTTATT TTGCTACAAA TAAACCCCTT		120
AAACTCTCTA TTTCCTCATA TTCTACCGCT TCATCGGTGG GTGTGTAAGA CGTACGTACG		180
TACAGCTGGG GCTGGCTTAC TGCGCACCGC TTATTTATTA CTTAATTCA ACACATTTA		240
TATCTTCTT CTTCTTTTT CTTGCTCTT CTTGTGAAA ATG GCG GTC TTC GAG		294
	Met Ala Val Phe Glu	
	1 5	
AAG AAT ACA CGC CCC AAG ATT GCT ATG GTG GGC TCC GGT ATG ATT GGA		342
Lys Asn Thr Arg Pro Lys Ile Ala Met Val Gly Ser Gly Met Ile Gly		
10 15 20		
GGC ACC ATG GCT TTC CTG TGC AGC TTG AGG GAA CTC GGA GAT GTT GTC		390
Gly Thr Met Ala Phe Leu Cys Ser Leu Arg Glu Leu Gly Asp Val Val		
25 30 35		
CTC TTC GAC GTT GTA CCG AAC ATG CCG ATG GGG AAG GCG ATG GAT ATA		438
Leu Phe Asp Val Val Pro Asn Met Pro Met Gly Lys Ala Met Asp Ile		
40 45 50		
TCG CAC AAT TCG TCG GTG GTT GAC ACG GGT ATA ACA GTA TAC GGC TCA		486
Ser His Asn Ser Ser Val Val Asp Thr Gly Ile Thr Val Tyr Gly Ser		
55 60 65		
AAT TCA TAC GAG TGC TTG AAG GGT GCG GAC GTA GTA ATA ATA ACA GCA		534
Asn Ser Tyr Glu Cys Leu Lys Gly Ala Asp Val Val Ile Ile Thr Ala		
70 75 80 85		
GGG ATA ACA AAG ATA CCC GGA AAG AGC GAT AAA GAA TGG TCT AGA ATG		582
Gly Ile Thr Lys Ile Pro Gly Lys Ser Asp Lys Glu Trp Ser Arg Met		
90 95 100		

GAT CTA TTA CCT GTG AAT ATA AAG ATA ATG AGG GAG GTC GGT GCA GCA	630		
Asp Leu Leu Pro Val Asn Ile Lys Ile Met Arg Glu Val Gly Ala Ala			
105	110	115	
ATT AAA TCT TAC TGT CCT AAT GCA TTT GTT ATT AAT ATA ACA AAT CCT	678		
Ile Lys Ser Tyr Cys Pro Asn Ala Phe Val Ile Asn Ile Thr Asn Pro			
120	125	130	
TTA GAT GTG ATG GTA GCT GCT CTT CAA GAG TCA TCA GGA CTA CCT CAT	726		
Leu Asp Val Met Val Ala Ala Leu Gln Glu Ser Ser Gly Leu Pro His			
135	140	145	
CAT AGA ATC TGC GGT ATG GCT GGG ATG CTT GAT AGC TCT CGT TTT AGA	774		
His Arg Ile Cys Gly Met Ala Gly Met Leu Asp Ser Ser Arg Phe Arg			
150	155	160	165
CGT ATG ATA GCT GAT AAA TTA GAA GTC TCT CCT AGA GAT GTA CAG GGG	822		
Arg Met Ile Ala Asp Lys Leu Glu Val Ser Pro Arg Asp Val Gln Gly			
170	175	180	
ATG GTC ATA GGT GTA CAC GGC GAT CAT ATG GTG CCC CTA AGT AGA TAT	870		
Met Val Ile Gly Val His Gly Asp His Met Val Pro Leu Ser Arg Tyr			
185	190	195	
GCA ACA GTT AAC GGC ATC CCG CTT TCT GAG TTT GTT AAG AAG GGC TGG	918		
Ala Thr Val Asn Gly Ile Pro Leu Ser Glu Phe Val Lys Lys Gly Trp			
200	205	210	-
ATC AAG CAA GAA GAA GTA GAT GAT ATC GTT CAG AAG ACC AAG GTC GCT	966		
Ile Lys Gln Glu Glu Val Asp Asp Ile Val Gln Lys Thr Lys Val Ala			
215	220	225	
GGA GGA GAG ATC GTA CGC CTA TTA GGA CAA GGC TCT GCT TAC TAT GCT	1014		
Gly Gly Glu Ile Val Arg Leu Leu Gly Gln Gly Ser Ala Tyr Tyr Ala			
230	235	240	245

CCA GGG GCT TCA GCT ATT CAG ATG GCT GAG AGC TAT CTA AAG GAT AGA	1062		
Pro Gly Ala Ser Ala Ile Gln Met Ala Glu Ser Tyr Leu Lys Asp Arg			
250	255	260	
AAG AGA GTG ATG GTT TGC TCT TGC TAC TTG CAA GGA CAA TAT GGT GTA	1110		
Lys Arg Val Met Val Cys Ser Cys Tyr Leu Gln Gly Gln Tyr Gly Val			
265	270	275	
CAG AAT CAC TAC TTA GGA GTA CCT TGT GTT ATC GGT GGG AGA GGT GTT	1158		
Gln Asn His Tyr Leu Gly Val Pro Cys Val Ile Gly Gly Arg Gly Val			
280	285	290	
GAG AAG ATT ATT GAG TTA GAA TTG ACC GCA CAA GAA AGA CAG GAG CTT	1206		
Glu Lys Ile Ile Glu Leu Glu Leu Thr Ala Gln Glu Arg Gln Glu Leu			
295	300	305	
CAG GGA TCT ATC GAT GAG GTT AAG GAG ATG CAG AAG GCT ATT GCT GCT	1254		
Gln Gly Ser Ile Asp Glu Val Lys Glu Met Gln Lys Ala Ile Ala Ala			
310	315	320	325
CTT GAT GCA TCC AAG TAAGCAGCAG CAAAATCGCA GAAGTTGCAG CGCTAGAAC	1309		
Leu Asp Ala Ser Lys			
330			
ACCAGCAGCA GCAGCAGCAG CAGCCTATAG TTCTTGCTGC TGCTGTCCT ACTACAGCTG	1369		
CGGCTTTCTT CCTCGTGTAA TTATCATGAT AGTAAGCTGC TGTACCGAGCA GCAGCAGCAG	1429		
CAGCAGATTT TGCTTGCACC GCCGTTGTT TTGCGTACAC CGGCAGAAAT ATTGACTTGC	1489		
AGTTAGGAGA AAGAAAGAAA ACAAACACGA TCCCACGAT CCCAATAAAC CCCACACTGT	1549		
CGATCCCACG GATCCCAGCA ACTCCACGGG GCTCTTAACG GTTAAACCTA TTATTCTTAT	1609		
CATTACTGTC TCCCGAATTC GATATCAAGC TTATCGATAC CGTCGACCTC GAGGGGGGGC	1669		
CCGGTACCCA	1679		

## (2) INFORMATION FOR SEQ ID NO: 2:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 330 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Ala Val Phe Glu Lys Asn Thr Arg Pro Lys Ile Ala Met Val Gly  
1 5 10 15

Ser Gly Met Ile Gly Gly Thr Met Ala Phe Leu Cys Ser Leu Arg Glu  
20 25 30

Leu Gly Asp Val Val Leu Phe Asp Val Val Pro Asn Met Pro Met Gly  
35 40 45

Lys Ala Met Asp Ile Ser His Asn Ser Ser Val Val Asp Thr Gly Ile  
50 55 60

Thr Val Tyr Gly Ser Asn Ser Tyr Glu Cys Leu Lys Gly Ala Asp Val  
65 70 75 80

Val Ile Ile Thr Ala Gly Ile Thr Lys Ile Pro Gly Lys Ser Asp Lys  
85 90 95

Glu Trp Ser Arg Met Asp Leu Leu Pro Val Asn Ile Lys Ile Met Arg  
100 105 110

Glu Val Gly Ala Ala Ile Lys Ser Tyr Cys Pro Asn Ala Phe Val Ile  
115 120 125

Asn Ile Thr Asn Pro Leu Asp Val Met Val Ala Ala Leu Gln Glu Ser  
 130 135 140

Ser Gly Leu Pro His His Arg Ile Cys Gly Met Ala Gly Met Leu Asp  
 145 150 155 160

Ser Ser Arg Phe Arg Arg Met Ile Ala Asp Lys Leu Glu Val Ser Pro  
 165 170 175

Arg Asp Val Gln Gly Met Val Ile Gly Val His Gly Asp His Met Val  
 180 185 190

Pro Leu Ser Arg Tyr Ala Thr Val Asn Gly Ile Pro Leu Ser Glu Phe  
 195 200 205

Val Lys Lys Gly Trp Ile Lys Gln Glu Glu Val Asp Asp Ile Val Gln  
 210 215 220

Lys Thr Lys Val Ala Gly Gly Glu Ile Val Arg Leu Leu Gly Gln Gly  
 225 230 235 240

Ser Ala Tyr Tyr Ala Pro Gly Ala Ser Ala Ile Gln Met Ala Glu Ser  
 245 250 255

Tyr Leu Lys Asp Arg Lys Arg Val Met Val Cys Ser Cys Tyr Leu Gln  
 260 265 270

Gly Gln Tyr Gly Val Gln Asn His Tyr Leu Gly Val Pro Cys Val Ile  
 275 280 285

Gly Gly Arg Gly Val Glu Lys Ile Ile Glu Leu Glu Leu Thr Ala Gln  
 290 295 300

Glu Arg Gln Glu Leu Gln Gly Ser Ile Asp Glu Val Lys Glu Met Gln  
 305 310 315 320

Lys Ala Ile Ala Ala Leu Asp Ala Ser Lys

325

330

Gly Arg Tyr Glu - Ser Glu Glu Glu Glu Glu Glu

CLAIMS.

1. A protein having one or more immunoreactive and/or antigenic determinants of *Eimeria* lactate dehydrogenase (LDH), said LDH having a relativve monomeric molecular mass of about 37,000.
2. A protein according to claim 1 wherein the *Eimeria* species is *Eimeria acervulina*.
3. A protein according to claim 1 characterized in that it comprises at least part of the amino acid sequence shown in SEQ ID NO. 2 or a biologically functional equivalent thereof.
4. A nucleic acid sequence encoding a protein according to any one of claims 1 to 3.
5. A nucleic acid sequence according to claim 4 characterized in that the nucleic acid sequence contains at least part of the DNA sequence shown in SEQ ID NO. 1.
6. A recombinant nucleic acid molecule comprising a nucleic acid sequence according to claim 4 or 5 operatively linked to expression control sequences enabling expression of said nucleic acid sequence.
7. A recombinant vector comprising a nucleic acid sequence according to claim 4 or 5.
8. A recombinant vector according to claim 7 characterized in that the nucleic acid sequence is operatively linked to expression control sequences.

9. A host cell or organism transformed with a nucleic acid sequence according to claim 4 or 5 or a recombinant nucleic acid molecule according to claim 6 or a recombinant vector molecule according to claim 7 or 8.

10. A process for expressing the protein according to any one of claims 1 to 3 comprising culturing a host cell according to claim 9.

11. A vaccine for the protection of poultry against coccidiosis characterized in that it comprises a protein according to any one of claims 1 to 3, a recombinant nucleic acid molecule according to claim 6, a recombinant vector according to claim 7 or claim 8, or a host cell or organism according to claim 9 together with a pharmaceutically acceptable carrier.

12. A process for the preparation of a coccidiosis vaccine comprising the steps of culturing an infected host cell according to claim 9, collecting the recombinant vector and formulating said recombinant vector into a pharmaceutical preparation with immunizing activity.

13. A process for the preparation of a coccidiosis vaccine comprising formulating a protein according to any one of claims 1 to 3 or a protein prepared according to the process of claim 10 into a pharmaceutical preparation with immunizing activity.

14. An antibody or antiserum immuno-reactive with a protein according to any one of claims 1 to 3.

15. A method for the protection of poultry against coccidiosis comprising administering a vaccine according to claim 11 to the birds.

## ABSTRACT.

This invention relates to novel *Eimeria* proteins with immunogenic properties as well as to DNA sequences encoding these proteins. These proteins can be administered to poultry thereby protecting the birds against coccidiosis. In addition the "DNA encoding these proteins can be used for the preparation of a vector vaccine against coccidiosis.

故其子曰：「吾父之子，其名何也？」

FIGURE 1





FIGURE 2



As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original first and joint inventor (if plural names are listed below) of the subject matter for which a patent is sought on the invention entitled Coccidiosis poultry vaccine

the specification of which

[CHECK ONE]

is attached hereto

[ ] was filed on \_\_\_\_\_ as Application Serial No. \_\_\_\_\_ and was amended on \_\_\_\_\_ [if applicable]

[ ] as filed under the Patent Cooperation Treaty on \_\_\_\_\_ Serial No. \_\_\_\_\_, The United States of America being designated.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined Title 37, Code of Federal Regulations Section 1.56(a)

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign applications(s) for patent or inventor's certificate having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)			Priority claimed		
<u>95201801.8</u>	<u>Europe</u>	<u>03-07-1995</u>	<u>V</u>	<u>Yes</u>	<u>No</u>
Number	Country	Day/Month/Year filed			
<u>                  </u>	<u>                  </u>	<u>                  </u>	<u>                  </u>	<u>Yes</u>	<u>No</u>
Number	Country	Day/Month/Year filed			
<u>                  </u>	<u>                  </u>	<u>                  </u>	<u>                  </u>	<u>Yes</u>	<u>No</u>
Number	Country	Day/Month/Year filed			

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the patent and Trademark

Office all information known to me to be material -- ~~material~~ as defined in Title 37, Code of Federal Regulation Section 1.56(a) which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)


(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

And I hereby appoint as principal attorney, William M. Blackstone, Registration No. 29,772, Mary E. Gormley, Registration No. 34,409 and Gregory R. Muir, Registration No. 35,293.


Please address all communications to:

William M. Blackstone  
AKZO NOBEL  
1300 Piccard Drive #206  
Rockville, MD 20850-4373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Jacobus Johannes KOK  
Inventor's signature  Date 11-7-96

Citizenship Dutch  
Residence and P.O. Address De Meeuwse Acker 1128, 6546 DH Nijmegen, The Netherlands

Full name of second joint inventor Paul van den BOOGAART  
Inventor's signature  Date 11-7-96

Citizenship Dutch  
Residence and P.O. Address Van Schaikstraat 43, 5344 SC Oss, The Netherlands

Full name of third joint inventor Arnodus Nicolaas VERMEULEN  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Citizenship Dutch  
Residence and P.O. Address Korhoenderveld 34, 5431 HH Cuyk, The Netherlands

Full name of fourth joint inventor \_\_\_\_\_  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Citizenship \_\_\_\_\_  
Residence and P.O. Address \_\_\_\_\_

As a below named inventor, I hereby declare th. :

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original first and joint inventor (if plural names are listed below) of the subject matter for which a patent is sought on the invention entitled Coccidiosis poultry vaccine

the specification of which

[CHECK ONE]

is attached hereto

[ ] was filed on \_\_\_\_\_ as Application Serial  
No. \_\_\_\_\_ and was amended on \_\_\_\_\_  
[if applicable]

[ ] as filed under the Patent Cooperation Treaty on \_\_\_\_\_  
Serial No. \_\_\_\_\_, The United States of America  
being designated.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined Title 37, Code of Federal Regulations Section 1.56(a)

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign applications(s) for patent or inventor's certificate having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)			Priority claimed		
Number	Country	Day/Month/Year filed	V	Yes	No
95201801.8	Europe	03-07-1995	<input checked="" type="checkbox"/>	Yes	<input type="checkbox"/>
Number	Country	Day/Month/Year filed	<input type="checkbox"/>	Yes	<input type="checkbox"/>
Number	Country	Day/Month/Year filed	<input type="checkbox"/>	Yes	<input type="checkbox"/>

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the patent and Trademark

defined in Title 37, Code of Federal Regulations, section 1.50(a), which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

And I hereby appoint as principal attorney, William M. Blackstone, Registration No. 29,772, Mary E. Gormley, Registration No. 34,409 and Gregory R. Muir, Registration No. 35,293.

Please address all communications to:

William M. Blackstone  
AKZO NOBEL  
1300 Piccard Drive #206  
Rockville, MD 20850-4373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Jacobus Johannes KOK  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Citizenship Dutch \_\_\_\_\_  
Residence and P.O. Address De Meeuwse Acker 1128, 6546 DH Nijmegen, The Netherlands \_\_\_\_\_

Full name of second joint inventor Paul van den BOOGAART  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Citizenship Dutch \_\_\_\_\_  
Residence and P.O. Address Van Schaikstraat 43, 5344 SC Oss, The Netherlands \_\_\_\_\_

Full name of third joint inventor Arnodus Nicolaas VERMEULEN  
Inventor's signature \_\_\_\_\_ Date 11 July 74 \_\_\_\_\_

Citizenship Dutch \_\_\_\_\_  
Residence and P.O. Address Korhoenderveld 34, 5431 HH Cuyk, The Netherlands \_\_\_\_\_

Full name of fourth joint inventor \_\_\_\_\_  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Citizenship \_\_\_\_\_  
Residence and P.O. Address \_\_\_\_\_

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original first and joint inventor (if plural names are listed below) of the subject matter for which a patent is sought on the invention entitled Coccidiosis poultry vaccine

the specification of which

[CHECK ONE]

is attached hereto

[ ] was filed on \_\_\_\_\_ as Application Serial  
No. \_\_\_\_\_ and was amended on \_\_\_\_\_  
[if applicable]

[ ] as filed under the Patent Cooperation Treaty on \_\_\_\_\_  
Serial No. \_\_\_\_\_, The United States of America  
being designated.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined Title 37, Code of Federal Regulations Section 1.56(a)

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign applications(s) for patent or inventor's certificate having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)			Priority claimed		
95201801.8	Europe	03-07-1995	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No	
Number	Country	Day/Month/Year filed	<input type="checkbox"/> Yes	<input checked="" type="checkbox"/> No	
Number	Country	Day/Month/Year filed	<input type="checkbox"/> Yes	<input checked="" type="checkbox"/> No	
Number	Country	Day/Month/Year filed	<input type="checkbox"/> Yes	<input checked="" type="checkbox"/> No	

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the patent and Trademark

Office all information known to me to be material as defined in Title 37, Code of Federal Regulation Section 1.56(a) which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

---

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

---


(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

And I hereby appoint as principal attorney, William M. Blackstone, Registration No. 29,772, Mary E. Gormley, Registration No. 34,409 and Gregory R. Muir, Registration No. 35,293.

Please address all communications to:

William M. Blackstone  
AKZO NOBEL  
1300 Piccard Drive #206  
Rockville, MD 20850-4373


I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Jacobus Johannes KOK  
Inventor's signature 

Date 11-7-96

Citizenship Dutch

Residence and P.O. Address De Meeuwse Acker 1128, 6546 DH Nijmegen, The Netherlands

Full name of second joint inventor Paul van den BOOGAART  
Inventor's signature 

Date 11-7-96

Citizenship Dutch


Residence and P.O. Address Van Schaikstraat 43, 5344 SC Oss, The Netherlands

Full name of third joint inventor Arnodus Nicolaas VERMEULEN  
Inventor's signature 

Date

Citizenship Dutch

Residence and P.O. Address Korhoenderveld 34, 5431 HH Cuyk, The Netherlands

Full name of fourth joint inventor    
Inventor's signature 

Date

Citizenship  

Residence and P.O. Address

As a below named inventor, I hereby declare the : 00000000000000000000000000000000

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original first and joint inventor (if plural names are listed below) of the subject matter for which a patent is sought on the invention entitled Coccidiosis poultry vaccine

the specification of which

[CHECK ONE]

is attached hereto

[ ] was filed on \_\_\_\_\_ as Application Serial  
No. \_\_\_\_\_ and was amended on \_\_\_\_\_  
[if applicable]

[ ] as filed under the Patent Cooperation Treaty on \_\_\_\_\_  
Serial No. \_\_\_\_\_, The United States of America  
being designated.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment referred to above.

I acknowledge the duty to disclose to the Patent and Trademark Office all information known to me to be material to patentability as defined Title 37, Code of Federal Regulations Section 1.56(a)

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign applications(s) for patent or inventor's certificate having a filing date before that of the application(s) on which priority is claimed:

Prior Foreign Application(s)			Priority claimed
95201801.8	Europe	03-07-1995	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	Day/Month/Year filed	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Number	Country	Day/Month/Year filed	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Number	Country	Day/Month/Year filed	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

I hereby claim the benefit under Title 35, United States Code, Section 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application(s) in the manner provided by the first paragraph of Title 35, United States Code, Section 112, I acknowledge the duty to disclose to the patent and Trademark

defined in Title 37, Code of Federal Regulations, section 1.15(a), which became available between the filing date of the prior application(s) and the national or PCT international filing date of this application.

(U.S. Serial No.) (Filing date) (Status-patented, pending, abandoned)

(U.S. Serial No. (Filing date) (Status-patented, pending, abandoned)

And I hereby appoint as principal attorney, William M. Blackstone, Registration No. 29,772, Mary E. Gormley, Registration No. 34,409 and Gregory R. Muir, Registration No. 35,293.

Please address all communications to:

William M. Blackstone  
AKZO NOBEL  
1300 Piccard Drive #206  
Rockville, MD 20850-4373

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor Jacobus Johannes KOK  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Citizenship Dutch  
Residence and P.O. Address De Meeuwse Acker 1128, 6546 DH Nijmegen, The Netherlands

Full name of second joint inventor Paul van den BOOGAART  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Citizenship Dutch  
Residence and P.O. Address Van Schaikstraat 43, 5344 SC Oss, The Netherlands

Full name of third joint inventor Arnodus Nicolaas VERMEULEN  
Inventor's signature \_\_\_\_\_ Date 11 July 1986

Citizenship Dutch  
Residence and P.O. Address Korhoenderveld 34, 5431 HH Cuyk, The Netherlands

Full name of fourth joint inventor \_\_\_\_\_  
Inventor's signature \_\_\_\_\_ Date \_\_\_\_\_

Citizenship \_\_\_\_\_  
Residence and P.O. Address \_\_\_\_\_